ERYTHROMYCIN LACTOBIONATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin Lactobionate, and what generic alternatives are available?
Erythromycin Lactobionate is a drug marketed by Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Gland, Nexus, and Teva Parenteral. and is included in six NDAs.
The generic ingredient in ERYTHROMYCIN LACTOBIONATE is erythromycin lactobionate. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the erythromycin lactobionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Erythromycin Lactobionate
A generic version of ERYTHROMYCIN LACTOBIONATE was approved as erythromycin lactobionate by NEXUS on February 14th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ERYTHROMYCIN LACTOBIONATE?
- What are the global sales for ERYTHROMYCIN LACTOBIONATE?
- What is Average Wholesale Price for ERYTHROMYCIN LACTOBIONATE?
Summary for ERYTHROMYCIN LACTOBIONATE
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Clinical Trials: | 5 |
| Patent Applications: | 2,196 |
| DailyMed Link: | ERYTHROMYCIN LACTOBIONATE at DailyMed |
Recent Clinical Trials for ERYTHROMYCIN LACTOBIONATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Prof Dr Jan Tack | N/A |
| Cempra Inc | Phase 2/Phase 3 |
| Biomedical Advanced Research and Development Authority | Phase 2/Phase 3 |
Pharmacology for ERYTHROMYCIN LACTOBIONATE
| Drug Class | Macrolide Antimicrobial Macrolide |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN LACTOBIONATE
US Patents and Regulatory Information for ERYTHROMYCIN LACTOBIONATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abraxis Pharm | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062604-002 | Nov 24, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Nexus | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 215290-001 | Feb 14, 2022 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Baxter Hlthcare | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062993-001 | May 9, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Teva Parenteral | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 063253-002 | Jul 30, 1993 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Abraxis Pharm | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062604-001 | Nov 24, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Baxter Hlthcare | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 062993-002 | May 9, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Gland | ERYTHROMYCIN LACTOBIONATE | erythromycin lactobionate | INJECTABLE;INJECTION | 216761-001 | Nov 19, 2024 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
